This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gary J. Beeman Appointed CEO Of GeneLink BioSciences, Inc.

ORLANDO, Fla., Feb. 18 /PRNewswire-FirstCall/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics, wellness, and biotechnology company (, is pleased to announce the appointment of Gary J. Beeman as its Chief Executive Officer and President, effective February 17, 2010.

Mr. Beeman is a seasoned public and private company CEO and entrepreneur, with a proven record of achieving fast growth and profitability for early stage technology companies.  Mr. Beeman brings over 30 years of experience in  senior management positions growing and operating leading edge global marketing and manufacturing companies.  Prior to joining GeneLink, Mr. Beeman most recently served as CEO and a founder of Bay Hill Ventures, a private capital firm.  Mr. Beeman has also served as Strategic Planning advisor to the GeneLink Board of Directors and as Director of Marketing Communications for GeneWize Life Sciences, Inc. during the past two years. Mr. Beeman succeeds David L. Macdonald, GeneLink's interim CEO, who will continue to work with GeneLink in a consulting capacity.    

"I'm excited and honored to lead the GeneLink team into its next major growth and profitability phase," said Gary Beeman, Chief Executive Officer, GeneLink BioSciences.    "With the untenable crisis in healthcare costs paving the way, wellness has finally become the economic driver that it always should have been- simply because sickness is no longer affordable.  GeneLink's 16 years of genomic and nutraceutical research and product development has perfectly positioned us to lead the new era of Genetically-guided Personalized Wellness products.  GeneLink is a true game-changer, and a business model that is sustainable for the long term. "

GeneWize Life Sciences, Inc. (, GeneLink's direct marketing subsidiary, is also pleased to announce that Sharon M. Tahaney has been named President of GeneWize, effective February 17, 2010.  Ms. Tahaney had previously been the Senior Vice President of Sales and Marketing for GeneWize.  In less than a year, Ms. Tahaney has developed and implemented the GeneWize Strategic Growth Plan including a brand lift, new pricing strategies, new marketing tools, and has taken over as the leader and face of GeneWize and its valued Affiliates.

"I am privileged to lead such an extraordinary team of Affiliates at GeneWize Life Sciences," said Ms. Tahaney.  "We are on a mission that's bigger than any one of us and requires all of us.  We connect the latest in biotechnology and genetic testing to custom-blend nutrition and skin care."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GNLK $0.00 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs